ONCOLOGY Vol 33 No 9

Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care.

With FDA-approved indications for both chronic lymphocytic leukemia and acute myeloid leukemia, and continued investigation within multiple disease states, venetoclax has become an exciting oral targeted therapy among oncologists. 

Clinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.

Most recently, the FDA approved cabozantinib for the treatment of HCC, but this drug has a history. 

ONCOLOGY spoke to Andre Goy, MD, MS about advances on leukemia, lymphoma, and myeloma treatments.

Many clinical trials in breast and endometrial cancers are underway and recruiting patients.

STUMP: Elevated PSA, family history, risk factors, and clinical findings. What is the next step in this case? Experts weigh in.

Therapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.